Daunted by the prospect of a lengthy safety review, Mountain View, CA-based Vivus is giving up on its program for an experimental testosterone therapy for women. The developer says it is shelving the Luramist program and returning the rights to a subsidiary of Acrux. "The decision to terminate the agreement was made in view of the significant long-term safety requirements for the approval of testosterone products in women," stated Peter Tam, president of Vivus, in a prepared statement. "We believe it is in our shareholders' best interests to pursue other therapeutic candidates." Tam plans to focus the company on its two leading therapies: Qnexa for obesity and avanafil for erectile dysfunction.
***
Set back for Acrux or an opportunity to renegotiate the female equivilent of Axiron in light of the massive deal?
Seems a waste of time for Acrux to have to now find a new party - hopefully Lilly will be interested. I wonder if there are any details as to contractual relief for this?
Daunted by the prospect of a lengthy safety review, Mountain...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.69M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 434 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 17258 | 1 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable